Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2013 2
2014 3
2019 3
2020 1
2021 5
2022 3
2023 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
Biological Biomarkers in Respiratory Diseases.
García-Río F, Alcázar-Navarrete B, Castillo-Villegas D, Cilloniz C, García-Ortega A, Leiro-Fernández V, Lojo-Rodriguez I, Padilla-Galo A, Quezada-Loaiza CA, Rodriguez-Portal JA, Sánchez-de-la-Torre M, Sibila O, Martínez-García MA. García-Río F, et al. Among authors: castillo villegas d. Arch Bronconeumol. 2022 Apr;58(4):323-333. doi: 10.1016/j.arbres.2022.01.003. Epub 2022 Jan 17. Arch Bronconeumol. 2022. PMID: 35312522 Free article. Review. English, Spanish.
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Richeldi L, et al. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836310 Free article. Clinical Trial.
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study.
Cano-Jiménez E, Villar Gómez A, Velez Segovia E, Aburto Barrenechea M, Sellarés Torres J, Francesqui J, Portillo Carroz K, Solis Solis AJ, Acosta Fernández O, Llanos González AB, Bordas-Martinez J, Cabrera Cesar E, Balcells Vilarnau E, Castillo Villegas D, Reyes Pardessus A, González Fernández C, García Moyano M, Urrutia Gajate A, Blanco Hortas A, Molina-Molina M. Cano-Jiménez E, et al. Among authors: castillo villegas d. ERJ Open Res. 2024 Feb 26;10(1):00405-2023. doi: 10.1183/23120541.00405-2023. eCollection 2024 Jan. ERJ Open Res. 2024. PMID: 38410707 Free PMC article.
Predictors and changes of physical activity in idiopathic pulmonary fibrosis.
Badenes-Bonet D, Rodó-Pin A, Castillo-Villegas D, Vicens-Zygmunt V, Bermudo G, Hernández-González F, Portillo K, Martínez-Llorens J, Chalela R, Caguana O, Sellarés J, Molina-Molina M, Duran X, Gea J, Rodríguez-Chiaradia DA, Balcells E. Badenes-Bonet D, et al. Among authors: castillo villegas d. BMC Pulm Med. 2022 Sep 9;22(1):340. doi: 10.1186/s12890-022-02134-4. BMC Pulm Med. 2022. PMID: 36085057 Free PMC article.
Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association.
Sebastiani M, Luppi F, Sambataro G, Castillo Villegas D, Cerri S, Tomietto P, Cassone G, Bocchino M, Atienza-Mateo B, Cameli P, Moya Alvarado P, Faverio P, Bargagli E, Vancheri C, Gonzalez-Gay MA, Clini E, Salvarani C, Manfredi A. Sebastiani M, et al. Among authors: castillo villegas d. J Clin Med. 2021 Jun 9;10(12):2548. doi: 10.3390/jcm10122548. J Clin Med. 2021. PMID: 34207641 Free PMC article.
Respiratory diseases registries in the national registry of rare diseases.
Lara Gallego B, Abaitua Borda I, Galán Gil G, Castillo Villegas D, Casanova Espinosa Á, Cano Jiménez E, Ojanguren Arranz I, Posada de la Paz M. Lara Gallego B, et al. Among authors: castillo villegas d. Arch Bronconeumol. 2014 Sep;50(9):397-403. doi: 10.1016/j.arbres.2014.02.007. Epub 2014 Apr 1. Arch Bronconeumol. 2014. PMID: 24703816 English, Spanish.
21 results